↓ Skip to main content

Survival and local control rates of triple-negative breast cancer patients treated with boost-IOERT during breast-conserving surgery

Overview of attention for article published in Strahlentherapie und Onkologie, September 2015
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
32 Dimensions

Readers on

mendeley
15 Mendeley
Title
Survival and local control rates of triple-negative breast cancer patients treated with boost-IOERT during breast-conserving surgery
Published in
Strahlentherapie und Onkologie, September 2015
DOI 10.1007/s00066-015-0895-2
Pubmed ID
Authors

Gerd Fastner, Cornelia Hauser-Kronberger, Angelika Moder, Roland Reitsamer, Franz Zehentmayr, Peter Kopp, Christoph Fussl, Thorsten Fischer, Heinrich Deutschmann, Felix Sedlmayer

Abstract

The purpose of this work was to retrospectively evaluate survival and local control rates of triple-negative breast cancer subtypes classified as five marker negative (5NP) and core basal (CB), respectively, after breast-conserving surgery and intraoperative boost radiotherapy with electrons (IOERT) followed by whole breast irradiation. A total of 71 patients with triple-negative breast cancer were enrolled, who were treated with lumpectomy, axillary lymph node dissection, and IOERT with 9.6 Gy (median Dmax) followed by normofractionated whole breast irradiation to median total doses of 54 Gy. Chemotherapy was applied in a neoadjuvant (12 %), adjuvant (75 %), or combinational setting (7 %). After a median follow-up of 97 months (range 4-170 months), 5 in-breast recurrences were detected (7.0 %). For all patients, 8-year actuarial rates for local control, metastases-free survival, disease-specific survival, and overall survival amounted to 89, 75, 80, and 69 %, respectively. All local recurrences occurred in grade 3 (G3) tumors irrespective of their specific immunohistochemical phenotype; thus, the local control rate for grades 1/2 (G1/2) was 100 % for both 5NP and CB, while for G3 it was 88 % for 5NP and 90 % for CB (p = 0.65 and 0.82, respectively, n.s.). For disease-specific survival, only the difference of the best-prognosis group 5-NP/G3 vs. the worst-prognosis cohort CB/G1/2 was statistically significant: 90 % vs. 54 % (p = 0.03). Boost-IOERT provides acceptable long-term in-breast control in triple negative breast cancer. The best subgroup in terms of disease-specific survival was represented by 5NP in combination with tumor grading G3.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 15 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 1 7%
Student > Postgraduate 1 7%
Unknown 13 87%
Readers by discipline Count As %
Medicine and Dentistry 2 13%
Business, Management and Accounting 1 7%
Unknown 12 80%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 September 2015.
All research outputs
#20,292,660
of 22,829,083 outputs
Outputs from Strahlentherapie und Onkologie
#532
of 751 outputs
Outputs of similar age
#230,515
of 274,665 outputs
Outputs of similar age from Strahlentherapie und Onkologie
#8
of 17 outputs
Altmetric has tracked 22,829,083 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 751 research outputs from this source. They receive a mean Attention Score of 2.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 274,665 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.